Market News

Today B. Riley FBR Reiterates a “Buy” Rating on Kindred Biosciences (KIN) and a $21.0 Target Price

Kindred Biosciences, Inc. (NASDAQ:KIN) Logo

Investors sentiment increased to 2 in 2018 Q2. Its up 1.22, from 0.78 in 2018Q1. It improved, as 3 investors sold Kindred Biosciences, Inc. shares while 16 reduced holdings. 15 funds opened positions while 23 raised stakes. 19.86 million shares or 17.97% more from 16.83 million shares in 2018Q1 were reported.

Metropolitan Life Insur New York, a New York-based fund reported 9,647 shares. Royal Bancorp Of Canada holds 0% or 8,039 shares in its portfolio. Moreover, Piedmont Invest Advsrs Ltd Company has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). Eam Invsts Lc reported 63,883 shares stake. Bnp Paribas Arbitrage has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Ameritas Invest Prtnrs holds 0% or 1,848 shares in its portfolio. Deutsche Bank Ag invested in 138,038 shares or 0% of the stock. 281,726 were accumulated by Geode Cap Mngmt Limited Com. Morgan Stanley holds 0.01% or 2.16 million shares in its portfolio. Vanguard Grp, a Pennsylvania-based fund reported 1.33M shares. 281,599 were reported by Ny State Common Retirement Fund. State Of Wisconsin Board accumulated 15,000 shares. Fred Alger Inc holds 0% or 9,000 shares. Sit Invest Assoc invested in 70,600 shares. Evanson Asset Management Llc invested in 16,545 shares or 0.03% of the stock.

Since May 18, 2018, it had 1 buying transaction, and 5 selling transactions for $6.44 million activity. $8.03 million worth of stock was bought by Park West Asset Management LLC on Wednesday, June 20.

Kindred Biosciences (KIN) Rating Reaffirmed

They currently have a $21.0 target on Kindred Biosciences (KIN). The target price by B. Riley FBR would suggest a potential upside of 181.88 % from the company’s last stock close price. This has been revealed to clients and investors in a report on 8 November.

The stock decreased 3.77% or $0.55 during the last trading session, reaching $14.04. About 288,830 shares traded or 29.31% up from the average. Kindred Biosciences, Inc. (KIN) has risen 85.33% since November 9, 2017 and is uptrending. It has outperformed by 69.71% the S&P500.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $474.55 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

More notable recent Kindred Biosciences, Inc. (NASDAQ:KIN) news were published by: Gurufocus.com which released: “Kindred Biosciences Announces Third Quarter 2018 Financial Results” on November 07, 2018, also Streetinsider.com with their article: “Kindred Biosciences (KIN) Announces Promotion of Co-Founder, COO Denise Bevers to President and Appoints to Board” published on October 23, 2018, Seekingalpha.com published: “Kindred Bio up 22% premarket on positive KIND-016 data” on October 31, 2018. More interesting news about Kindred Biosciences, Inc. (NASDAQ:KIN) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie” published on November 07, 2018 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs” with publication date: November 04, 2018.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*